Cardiovascular system in Children with Cystic fibrosis

Cardiovascular system in Children with Cystic fibrosis - Triple C

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37600

Enrollment

Registered

2012-12-17

Start date

2013-01-28

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CF or mucoviscidosis Cystic Fibrosis

Interventions

None listed

Eligibility

Age

2 Years to 11 Years

Inclusion criteria

Inclusion criteria: Children with cystic fibrosis: • Aged 3-12 years • Who visit the pediatric pulmonology department for their regular control visit;Health controls • Aged 3-12 year • Participating in the WHISTLER study

Exclusion criteria

Exclusion criteria: Children with cystic fibrosis: • Children with a history of a heart defect will be excluded from this study.;Healthy controls • Children with a history of a heart defect will be excluded from this study.

Design outcomes

Primary

Measure	Time frame
The main study parameters are the echocardiographic measurements of the cardiovascular system (diastolic function of the right and left ventricle).	—

Secondary

Measure	Time frame
Secundary study outcome is arterial stiffness (pulse wave velocity) and the respiratory system (the lung function measurement).	—

Countries

Netherlands

Outcome results